EE147 The Cost-Effectiveness of Olaparib Compared to Niraparib in the Treatment of Recurrent Ovarian Cancer Caused By BRCA1 and BRCA2 Gene Mutation from a US Healthcare Payer Perspective.
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.397
https://www.valueinhealthjournal.com/article/S1098-3015(22)00598-8/fulltext
Title :
EE147 The Cost-Effectiveness of Olaparib Compared to Niraparib in the Treatment of Recurrent Ovarian Cancer Caused By BRCA1 and BRCA2 Gene Mutation from a US Healthcare Payer Perspective.
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00598-8&doi=10.1016/j.jval.2022.04.397
First page :
Section Title :
Open access? :
No
Section Order :
10352